MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2016 International Congress

    Elemental profiles as biomarkers for diagnosis and disease progression of Parkinson’s disease

    F. Maass, M. Börger, A. Fischbach, B. Michalke, M. Bähr, I. Zerr, P. Lingor (Göttingen, Germany)

    Objective: This study aims to analyse the elemental profiles in the cerebrospinal fluid (CSF) of patients with idiopathic Parkinson´s disease (PD) and age-matched control patients…
  • 2016 International Congress

    PERFORM: Controlled study in fluctuating PD patients examining the effects of motor state on the outcomes resulting from a structured physical therapy (PT) program

    J.P. Hubble, B. Fisher, K. Lyons, C. McLean, G. Petzinger, R. Pahwa (Louisville, KY, USA)

    Objective: To determine if outcomes following a PT program are improved if PT sessions are conducted while PD patients are in an on motor state…
  • 2016 International Congress

    Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

    N.K. Majbour, N.N. Vaikath, K.D. Dijk, M. Ardah, C.E. Teunissen, H.W. Berendse, W.D.J. Berg, O.M.A. El-Agnaf (Amsterdam, Netherlands)

    Objective: To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for Parkinson's disease (PD). Background: Despite decades of intensive research, to date,…
  • 2016 International Congress

    A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients

    K. Kieburtz, C.W. Olanow, Y. Cohen, S. Oren (Rochester, NY, USA)

    Objective: To evaluate the efficacy, safety & tolerability of continuous subcutaneous infusion regimens of ND0612H. Background: L-dopa remains the most effective PD medication, however oral…
  • 2016 International Congress

    Long-term safety of levodopa-carbidopa intestinal gel from an ongoing, open-label, phase 3 continued access to treatment study in advanced Parkinson’s disease patients

    R.L. Rodriguez, C. Zadikoff, A.J. Espay, V.S.C. Fung, C. Hall, W.Z. Robieson, K. Chatamra, S. Eaton, M.F. Facheris, J. Benesh (Orlando, FL, USA)

    Objective: To assess the safety and tolerability of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) in advanced Parkinson's disease…
  • 2016 International Congress

    Body position during sleep in patients with Parkinson’s disease (PD): A sensor-based analysis

    J. Sringean, P. Taechalertpaisarn, C. Thanawattano, R. Bhidayasiri (Nonthaburi, Thailand)

    Objective: To identify the body position during sleep in PD patients in comparison to their spouses by using multisite wearable inertial sensors. Background: Nocturnal hypokinesia…
  • 2016 International Congress

    STEADY-PD III. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease. Baseline characteristics of the enrolled cohort

    T. Simuni, K.M. Biglan, J. Lowell, K. Hodgeman, B. Greco, R. Rockhill, D. Oakes (Chicago, IL, USA)

    Objective: To evaluate the efficacy of isradipine 10 mg daily on PD disability. Background: Isradipine, a dihydropyridine calcium channel antagonist with excellent penetration of the…
  • 2016 International Congress

    Deep brain stimulation effect on the quality of life of individuals with Parkinson’s disease

    A. Ayres, M. Ghisi, A.M. Freiry, B.S.F. Oliveira, A.F.S. Schuch, C.R.M. Rieder, M.R. Olchik (Porto Alegre, Brazil)

    Objective: To identify the perception of QOL in individuals with PD pre and post DBS. Background: The DBS is one type of effective treatment in…
  • 2016 International Congress

    Does body mass index influence outcome of deep brain stimulation in Parkinson’s patients?

    H. Abboud, G. Genc, D. Reyes, N.R. Thompson, R. Cerejo, K. Wilson, A. Ahmed, M. Gostkowski, A. Machado, H.H. Fernandez (Cleveland, OH, USA)

    Objective: To investigate if preoperative body mass index (BMI) can predict functional and quality of life (QOL) outcomes following deep brain stimulation surgery (DBS) in…
  • 2016 International Congress

    Effect of bilateral subthalamic nuclei deep brain stimulation on impulse control disorders in PD

    R. Borgohain, P.K. Pesala, R.K. Mridula, A.K. Puligopu, V.V.P. Kagita, S.A. Jabeen, M.A. Kanikannan (Hyderabad, India)

    Objective: To study the effects of bilateral subthalamic nuclei stimulation on impulse control disorders(ICDs) in Parkinson's disease (PD). Background: Impulse control disorders(ICDs) cause significant morbidity…
  • « Previous Page
  • 1
  • …
  • 393
  • 394
  • 395
  • 396
  • 397
  • …
  • 405
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley